1-4 of 4
Alem A. Belachew
Close
Sort by
Journal Articles

The Prognostic Advantage of Calreticulin Mutations in Myelofibrosis Might be Confined to Type 1 or “type 1-like” Calreticulin Variants

Ayalew Tefferi, MD, Terra L Lasho, PhD, Alexander Tischer, PhD, Emnet A Wassie, MD, Christy Finke, BS, Alem A Belachew, Rhett Ketterling, MD, Curtis A Hanson, MD, Animesh Pardanani, MBBS, PhD
Journal: Blood
Blood (2014) 124 (21): 3166.
https://doi.org/10.1182/blood.V124.21.3166.3166
Published: 2014
Journal Articles

Revised Cytogenetic Risk Stratification in Primary Myelofibrosis: A Mayo Clinic Study of 903 Patients

Ayalew Tefferi, MD, Emnet A Wassie, MD, Kebede Begna, MD, Christy Finke, BS, Alem A Belachew, Naseema Gangat, MD, Terra L Lasho, PhD, Animesh Pardanani, MBBS, PhD, Curtis A. Hanson, MD, Rhett Ketterling, MD
Journal: Blood
Blood (2014) 124 (21): 631.
https://doi.org/10.1182/blood.V124.21.631.631
Published: 2014
Journal Articles

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis

CME Clinical Trials & Observations
Ayalew Tefferi, Paola Guglielmelli, Dirk R. Larson, Christy Finke, Emnet A. Wassie, Lisa Pieri, Naseema Gangat, Rajmonda Fjerza, Alem A. Belachew, Terra L. Lasho, Rhett P. Ketterling, Curtis A. Hanson, Alessandro Rambaldi, Guido Finazzi, Juergen Thiele, Tiziano Barbui, Animesh Pardanani, Alessandro M. Vannucchi
Journal: Blood
Blood (2014) 124 (16): 2507–2513.
https://doi.org/10.1182/blood-2014-05-579136
Published: 2014
Includes: Supplemental data
Journal Articles

The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants

Clinical Trials & Observations
Ayalew Tefferi, Terra L. Lasho, Alexander Tischer, Emnet A. Wassie, Christy M. Finke, Alem A. Belachew, Rhett P. Ketterling, Curtis A. Hanson, Animesh D. Pardanani
Journal: Blood
Blood (2014) 124 (15): 2465–2466.
https://doi.org/10.1182/blood-2014-07-588426
Published: 2014
Includes: Supplemental data